Literature DB >> 25284446

Incremental cost-effectiveness of percutaneous versus surgical closure of atrial septal defects in children under a public health system perspective in Brazil.

Rodrigo Costa1, Carlos A C Pedra, Marcelo Ribeiro, Simone Pedra, André Luis Ferreira-Da-Silva, Carisi Polanczyk, Otávio Berwanger, Alexandre Biasi, Rodrigo Ribeiro.   

Abstract

INTRODUCTION: Cost-effectiveness (CE) studies of percutaneous (PC) versus surgical (SC) atrial septal defect closure are lacking.
METHODS: A systematic literature review in children and a CE analysis based on a model of long-term outcomes were performed. Direct costs of PC and SC were US$8700 (defined arbitrarily) and US$5700 (actually paid), respectively. Three-times the Brazilian GDI (US$28,700) per year of life saved (with a discount rate of 5%) was used as a limit for willingness-to-pay. DISCUSSION: PC had a high (US$104,500) incremental CE ratio despite lower complication rates, shorter hospital stay and better (nonsignificant) adjusted life expectancy. PC would be cost-effective if it cost US$6400 or SC had an 8% loss of utility or its indirect costs were US$2250. Costs of PC should be reduced to be cost-effective in the Brazilian public health system. Indirect costs and impact on quality of life should be further assessed.

Entities:  

Keywords:  atrial septal defect; cost–effectiveness; public health; surgery; transcatheter

Mesh:

Year:  2014        PMID: 25284446     DOI: 10.1586/14779072.2014.967216

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  2 in total

1.  Estimation of Value-Based Price for Five High-Technology Medical Devices Approved by a Regional Health Technology Assessment Committee in Italy.

Authors:  Andrea Messori; Sabrina Trippoli
Journal:  Cureus       Date:  2022-05-03

Review 2.  Economic Analysis of Children's Surgical Care in Low- and Middle-Income Countries: A Systematic Review and Analysis.

Authors:  Anthony T Saxton; Dan Poenaru; Doruk Ozgediz; Emmanuel A Ameh; Diana Farmer; Emily R Smith; Henry E Rice
Journal:  PLoS One       Date:  2016-10-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.